|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C12N 15/11 | |
| C12N 15/113 | |||
| A61K 47/54 | |||
| C07H 21/04 | |||
| C07H 1/00 | |||
| C07H 99/00 |
| (11) | Number of the document | 3569711 |
| (13) | Kind of document | T |
| (96) | European patent application number | 19180844.3 |
| Date of filing the European patent application | 2015-12-15 | |
| (97) | Date of publication of the European application | 2019-11-20 |
| (45) | Date of publication and mention of the grant of the patent | 2021-02-03 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 201462092241 P | 2014-12-15 | US | |
| 201462092238 P | 2014-12-15 | US | |
| 201562187856 P | 2015-07-02 | US | |
| 201562187848 P | 2015-07-02 | US |
| (72) |
BROWN, Bob, Dale, US
WANG, Weimin, US
|
| (73) |
Dicerna Pharmaceuticals, Inc.,
33, Hayden Avenue, Lexington, MA 02421,
US
|
| (54) | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS |
| LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS |